Recently, monoclonal antibody Itolizumab, which targets the ALCAM-CD6 interaction, has been proved to alleviate several inflammatory conditions, such as arthritis, psoriasis and Covid-19 (42–44). The gene discussed is CD6; the disease is psoriasis.